SOPHiA GENETICS and Synnovis Partner to Expand Blood-Based Cancer Testing in the UK

SOPHiA GENETICS has partnered with Synnovis to expand access to blood-based cancer testing across the United Kingdom, announced in a press release. The collaboration supports NHS England's blood test-first program, which aims to speed up diagnosis and treatment for lung and breast cancer patients.

Synnovis has introduced the MSK-ACCESS test powered with SOPHiA DDM, originally developed by Memorial Sloan Kettering Cancer Center. The test detects actionable genomic alterations from a single blood draw and uses AI to analyze circulating tumor DNA. It allows for earlier targeted therapy and reduces the need for invasive testing.

Following a successful pilot, Synnovis now supports about 400 patients each month with liquid biopsy testing. The partners expect to test around 7,000 patients annually, representing one third of all such tests in England. The collaboration also enables Synnovis to expand testing to additional cancer types in future NHS screening programs.

The system integrates AccuGenomics technology for improved accuracy and uses a matched tumor-normal approach to minimize false positives. Through this program, Synnovis contributes to scaling NHS England's genomic testing infrastructure while maintaining compliance with national data security standards.